Rockefeller Capital Management
VIR icon

Rockefeller Capital Management’s Vir Biotechnology VIR Stock Holding History

Rockefeller Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$440K Buy
39,373
+114
+0.3% +$1.14K ﹤0.01% 2200
2026
Q2 		$400K Sell
39,259
-64
-0.2% -$609 ﹤0.01% 2210
2026
Q1 		$352K Buy
39,323
+9,454
+32% +$75.3K ﹤0.01% 2168
2025
Q4 		$180K Buy
29,869
+19,472
+187% +$116K ﹤0.01% 2429
2025
Q3 		$59.4K Buy
+10,397
New +$53.2K ﹤0.01% 2822
2023
Q1 		– Sell
-4,726
Closed -$119K – 3826
2022
Q4 		$119K Sell
4,726
-47
-1% -$1.15K ﹤0.01% 1941
2022
Q3 		$92K Buy
4,773
+4,652
+3,845% +$118K ﹤0.01% 2035
2022
Q2 		$3K Buy
+121
New +$2.82K ﹤0.01% 3708
2021
Q3 		– Sell
-13,832
Closed -$653K – 3856
2021
Q2 		$653K Hold
13,832
– – ﹤0.01% 1090
2021
Q1 		$709K Buy
13,832
+9,001
+186% +$485K ﹤0.01% 908
2020
Q4 		$129K Buy
+4,831
New +$157K ﹤0.01% 1345

Other funds holding VIR

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Rockefeller Capital Management's VIR Position: Q3 2026 in Review

Rockefeller Capital Management increased its Vir Biotechnology (VIR) stake by 0.29% in Q3 2026, buying an estimated $1.14K and bringing the position to 39,373 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #2200.

Rockefeller Capital Management first reported a position in VIR in Q4 2020 and has held it in 11 quarters since. The position peaked at $709K in Q1 2021. 202 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

  • Rockefeller Capital Management held 39,373 shares of Vir Biotechnology worth $440K as of Q3 2026.
  • Rockefeller Capital Management bought 114 Vir Biotechnology shares in Q3 2026, an estimated $1.14K.
  • Vir Biotechnology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #2200 holding.
  • Rockefeller Capital Management first reported a position in Vir Biotechnology in Q4 2020 and has held it in 11 quarters since.
  • Rockefeller Capital Management's Vir Biotechnology position peaked at $709K in Q1 2021.
  • 202 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.